Moreover, genetic variants in PLD3 have been linked with cerebrospinal fluid total-tau and phosphorylated-tau levels (19) and cognitive function in AD patients (40) and additionally associated with other neurological traits like longevity (41). This evidence concerns the gene MAPT and Alzheimer disease.